Diman Medical Secures Nearly Tens of Millions RMB in Funding to Advance Digital Solutions for Neurosurgical Perioperative Care

VCBeat has learned that Shenzhen Diman Medical Technology Co., Ltd. (hereinafter referred to as “Diman Medical”) successfully completed a financing round of nearly RMB 10 million in mid-2023. This round was exclusively invested by the Zhongfu Capital Angel Fund, under the China Academy of Science and Technology for Development (funded by the Shenzhen Angel Fund of Funds). The proceeds from this financing will be primarily used for R&D investment across product pipelines for multi-parameter cranial monitoring, as well as team expansion.

Shenzhen Diman Medical Technology Co., Ltd. was established in November 2021. Its core team comprises interdisciplinary experts, including clinical specialists, artificial intelligence algorithm experts, multi-parameter chip hardware engineers, high-performance computing specialists, and medical device sales professionals. With outstanding comprehensive capabilities and abundant industry resources, the company is dedicated to deeply integrating clinical insights with advanced technologies in the field of multi-parameter intracranial monitoring. It aims to capture opportunities in the domestic substitution market for high-value neurosurgical equipment and consumables, a market valued at tens of billions of RMB, by developing innovative products that truly meet clinical needs. In the future, the company plans to build big data application scenarios for multi-parameter intracranial monitoring and expand into the trillion-RMB blue ocean market of neuromodulation and brain science.

Neurosurgical conditions are highly complex, associated with numerous complications and significant variability in prognosis, thereby creating a strong demand for digital healthcare solutions. Addressing the specific needs of neurosurgery departments for specialized ICU care, Diman Medical provides high-end digital-medical-grade chips, intelligent devices, and digital consumables, offering comprehensive coverage of multi-parameter monitoring requirements in clinical practice. This approach improves patient survival rates and alleviates clinical workload. The company has already collaborated with multiple large tertiary hospitals to conduct preclinical studies, receiving robust support from the clinical community.

The company has established five major technological systems to achieve integrated multimodal monitoring of the craniocerebral region, built a specialized clinical database for neurosurgery, and developed a digital bedside monitoring system for neurosurgical care. These innovations provide novel patient management tools for neurosurgical clinical practice, facilitating the determination of targeted thresholds and treatment decisions for personalized precision medicine. Currently, the company has laid out more than ten R&D pipelines, obtained two registration certificates, and expects 2–3 product pipelines to be approved for clinical trials in 2024. The company is projected to reach an annual production capacity of tens of thousands of units and generate tens of millions in revenue in 2024.

Shenzhen Zhongke Incubation Equity Investment Fund Management Co., Ltd. (hereinafter referred to as “Zhongfu Capital”) is a wholly-owned private equity investment platform under China Academy of Science and Technology Development Co., Ltd. As a member of the fund cluster of Shenzhen Capital Group, a Shenzhen municipal state-owned enterprise, Zhongfu Capital focuses on identifying high-growth early-stage technology enterprises, promoting the incubation of tech startups and the commercialization and industrialization of scientific and technological achievements. It is committed to improving the essential elements for the development of technology enterprises through ecosystem integration, fostering new drivers for regional development through industrial convergence, and building a closed loop for the transformation of scientific and technological achievements through capital empowerment.